Science Corporation has received CE mark approval from Europe's medical device regulator to begin selling PRIMA, a retinal implant designed to restore vision lost to age-related macular degeneration (TechCrunch; Science Corporation). The approval covers form vision restoration, meaning patients can perceive shapes and read letters, numbers, and words, a first for a brain-computer interface device (Science Corporation).

PRIMA pairs an implantable chip with camera-equipped glasses. The chip is placed at the back of the eye during an hour-long outpatient procedure, and the glasses capture visual information that the chip converts into electrical signals the retina can process. Clinical trials were conducted in Germany (TechCrunch).

In those trials, PRIMA was the only treatment to successfully restore form vision to patients blinded by late-stage macular degeneration (Science Corporation). The trial's Data Safety Monitoring Board, an independent group that reviews clinical trial safety, voted in November 2024 to recommend the device for European regulatory submission (Science Corporation.

The first commercial PRIMA procedure in Europe could take place as early as September 2026. Each device is expected to cost in the hundreds of thousands of dollars (TechCrunch).

Science Corporation founder and CEO Max Hodak co-founded Neuralink and left that company in 2021 to start the firm. Science Corporation acquired Pixium, the French company that originally developed the PRIMA technology, in 2024 (TechCrunch).

On the US side, PRIMA has received an FDA designation that constitutes the first step toward expedited regulatory review for two rare forms of blindness (TechCrunch). The specific designation was not detailed in the available reporting, but the pathway positions PRIMA for a potential US market entry should clinical and regulatory milestones be met.

Beyond PRIMA, Science Corporation is working with Dr. Murat Günel, chair of Yale Medical School's Department of Neurosurgery, to develop surgical procedures for human trials of a directly implanted bio-hybrid brain sensor (TechCrunch). That program is earlier-stage and distinct from the retinal implant, but it signals the company's broader interest in implanted neural interfaces that go beyond sensory restoration.

The CE mark matters for what it concretely enables: commercial sale across EU member states under a unified regulatory framework, with reimbursement pathways that typically follow. A device priced in the hundreds of thousands of dollars per unit will face scrutiny on cost-effectiveness, but the addressable population is significant. Late-stage AMD progresses to geographic atrophy, a condition in which cells in the macula deteriorate and current therapeutic options are limited. PRIMA's trial data showed form vision restoration in precisely that cohort.

The competitive positioning is worth noting. Neuralink, the company Hodak co-founded before departing, has pursued a cortical implant approach, placing electrodes directly on the brain's surface for broader neurological applications. Science Corporation, by acquiring Pixium's retinal technology and pursuing a distinct bio-hybrid sensor pipeline, is taking a different architectural path: starting with a sensory endpoint, the retina, where the input-output mapping is comparatively well understood, rather than beginning with cortical interfaces where signal interpretation remains substantially harder. The CE mark gives PRIMA a commercial beachhead that Neuralink does not yet have in any market.

The historical parallel here is instructive. Earlier retinal prosthesis efforts, notably Argus II, approved by the FDA in 2013 for retinitis pigmentosa, used implanted electrodes to produce perceptible phosphenes, small flashes of perceived light. But they struggled with the resolution needed for form vision and reading. PRIMA's trial results claiming restored letter and word recognition suggest a different performance envelope. Whether that holds in a broader commercial population, with variable surgeon experience and patient anatomy, is the question the September rollout will begin to answer.

The pricing also bears watching. At hundreds of thousands of dollars per device, PRIMA sits in the range of other advanced implantable neurostimulation systems. European health systems will need to see durable functional outcomes and quality-of-life gains to justify reimbursement at that price point. The trial data is encouraging; post-market real-world evidence will be the arbiter.

For now, a neurotechnology company founded five years ago has a CE-marked product addressing a condition with profound unmet need. The September commercial launch will be the first concrete test of whether PRIMA can move from a controlled trial setting into clinical practice.